Pieris Pharmaceuticals, Inc.

Informe acción NasdaqCM:PIRS

Capitalización de mercado: US$21.1m

Pieris Pharmaceuticals Crecimiento futuro

Future controles de criterios 0/6

Actualmente no disponemos de suficiente cobertura de analistas para prever el crecimiento y los ingresos de Pieris Pharmaceuticals.

Información clave

n/a

Tasa de crecimiento de los beneficios

n/a

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs28.4%
Tasa de crecimiento de los ingresosn/a
Rentabilidad financiera futuran/a
Cobertura de analistas

None

Última actualizaciónn/a

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

The Market Doesn't Like What It Sees From Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Revenues Yet As Shares Tumble 30%

Jul 11
The Market Doesn't Like What It Sees From Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Revenues Yet As Shares Tumble 30%

Why Investors Shouldn't Be Surprised By Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) 27% Share Price Plunge

Apr 21
Why Investors Shouldn't Be Surprised By Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) 27% Share Price Plunge

We Think Pieris Pharmaceuticals (NASDAQ:PIRS) Needs To Drive Business Growth Carefully

Mar 19
We Think Pieris Pharmaceuticals (NASDAQ:PIRS) Needs To Drive Business Growth Carefully

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Not Doing Enough For Some Investors As Its Shares Slump 27%

Dec 18
Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Not Doing Enough For Some Investors As Its Shares Slump 27%

We Think Pieris Pharmaceuticals (NASDAQ:PIRS) Needs To Drive Business Growth Carefully

Aug 18
We Think Pieris Pharmaceuticals (NASDAQ:PIRS) Needs To Drive Business Growth Carefully

Analysts Just Shaved Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Forecasts Dramatically

May 15
Analysts Just Shaved Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Forecasts Dramatically

Why Investors Shouldn't Be Surprised By Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) 41% Share Price Plunge

Apr 17
Why Investors Shouldn't Be Surprised By Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) 41% Share Price Plunge

Can Pieris Pharmaceuticals (NASDAQ:PIRS) Afford To Invest In Growth?

Dec 31
Can Pieris Pharmaceuticals (NASDAQ:PIRS) Afford To Invest In Growth?

Bearish: This Analyst Is Revising Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Revenue and EPS Prognostications

Aug 10
Bearish: This Analyst Is Revising Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Revenue and EPS Prognostications

Pieris Pharmaceuticals GAAP EPS of -$0.14 misses by $0.03, revenue of $3.7M misses by $6.77M

Aug 04

Pieris: Early Stage Developer Of Novel Asset Class

Jan 09

We're Not Very Worried About Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate

Dec 15
We're Not Very Worried About Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate

Progress At Pieris Pharmaceuticals

Oct 27

Analysts Just Made A Noticeable Upgrade To Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Forecasts

Aug 05
Analysts Just Made A Noticeable Upgrade To Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Forecasts

We Think Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) CEO Compensation Package Needs To Be Put Under A Microscope

Jun 19
We Think Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) CEO Compensation Package Needs To Be Put Under A Microscope

Need To Know: Analysts Just Made A Substantial Cut To Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Estimates

May 22
Need To Know: Analysts Just Made A Substantial Cut To Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Estimates

Will Pieris Pharmaceuticals (NASDAQ:PIRS) Spend Its Cash Wisely?

May 19
Will Pieris Pharmaceuticals (NASDAQ:PIRS) Spend Its Cash Wisely?

Analysts Are Betting On Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) With A Big Upgrade This Week

Apr 01
Analysts Are Betting On Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) With A Big Upgrade This Week

Here's What Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Shareholder Ownership Structure Looks Like

Mar 08
Here's What Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Shareholder Ownership Structure Looks Like

We're Keeping An Eye On Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate

Feb 01
We're Keeping An Eye On Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate

How Much Did Pieris Pharmaceuticals'(NASDAQ:PIRS) Shareholders Earn From Share Price Movements Over The Last Three Years?

Dec 28
How Much Did Pieris Pharmaceuticals'(NASDAQ:PIRS) Shareholders Earn From Share Price Movements Over The Last Three Years?

How Does Pieris Pharmaceuticals' (NASDAQ:PIRS) CEO Salary Compare to Peers?

Dec 02
How Does Pieris Pharmaceuticals' (NASDAQ:PIRS) CEO Salary Compare to Peers?

En esta sección solemos presentar previsiones de crecimiento de ingresos y beneficios basadas en las estimaciones por consenso de analistas profesionales para ayudar a los inversores a comprender la capacidad de la empresa para generar beneficios. Pero como Pieris Pharmaceuticals no ha proporcionado suficientes datos anteriores y no dispone de previsiones de analistas, sus beneficios futuros no pueden calcularse de forma fiable extrapolando datos anteriores o utilizando las previsiones de los analistas.

Es una situación poco común, ya que el 97% de las empresas disponibles en SimplyWall St sí disponen de datos financieros anteriores.

Previsiones de crecimiento de beneficios e ingresos

NasdaqCM:PIRS - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
FechaIngresosBeneficiosFlujo de caja libreFlujo de caja operativoNúm. de analistas medio
9/30/20241-16-28-28N/A
6/30/202421-24-38-38N/A
3/31/202441-16-50-50N/A
12/31/202343-25-54-54N/A
9/30/202347-28-47-47N/A
6/30/202333-27-46-46N/A
3/31/202317-41-49-48N/A
12/31/202226-33-61-60N/A
9/30/202228-35-59-58N/A
6/30/202227-42-65-64N/A
3/31/202227-47-19-18N/A
12/31/202131-46-9-8N/A
9/30/202125-51-11-10N/A
6/30/202124-48-3-3N/A
3/31/202132-38-44-43N/A
12/31/202029-37-49-46N/A
9/30/202045-26-50-46N/A
6/30/202057-15-56-52N/A
3/31/202051-22-57-52N/A
12/31/201946-28-55-52N/A
9/30/201934-36-49-48N/A
6/30/201927-40-51-49N/A
3/31/201933-28-49-48N/A
12/31/201829-27-3-1N/A
9/30/201842-813N/A
6/30/201838-8N/A53N/A
3/31/201828-18N/A55N/A
12/31/201725-18N/A50N/A
9/30/201710-32N/A48N/A
6/30/20177-31N/A9N/A
3/31/20176-27N/A9N/A
12/31/20166-23N/A-14N/A
9/30/20165-19N/A-10N/A
6/30/20165-17N/A-10N/A
3/31/20164-15N/A-7N/A
12/31/20153-14N/A-13N/A
9/30/20154-15N/A-10N/A
6/30/20154-13N/A-8N/A
3/31/20154-13N/A-8N/A
12/31/20145-10N/A-5N/A
9/30/20146-5N/A-6N/A
12/31/2013120N/A-3N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Datos insuficientes para determinar si el crecimiento previsto de los beneficios de PIRS es superior a la tasa de ahorro (2.6%).

Beneficios vs. Mercado: Datos insuficientes para determinar si se prevé que los beneficios de PIRS crezcan más rápidamente que el mercado US

Beneficios de alto crecimiento: Datos insuficientes para determinar si se espera que los beneficios de PIRS crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: No hay datos suficientes para determinar si se prevé que los ingresos de PIRS crezcan más rápidamente que el mercado de US.

Ingresos de alto crecimiento: No hay datos suficientes para determinar si se prevé que los ingresos de PIRS crezcan a un ritmo superior a 20% al año.


Previsiones de crecimiento de los beneficios por acción


Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de PIRS se prevé que sea elevada dentro de 3 años.


Descubre empresas en crecimiento